noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Royalty Pharma plc

Notice of Proposed Sale of Securities (Form 144)
Nexalin Technology Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)
California Department of[...]

Southbound I-5 Closed at SR-54 Evening of September 30

Healthcare

Biomea Fusion Inc.

09/22/2026 | Press release | Distributed by Public on 09/22/2026 14:01

Material Event (Form 8-K)

Item 8.01. Other Events.

On September 22, 2026, Biomea Fusion, Inc. (the "Company") updated the anticipated timing for topline results from the Company's ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers, which are now expected in October 2026.

Biomea Fusion Inc. published this content on September 22, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 22, 2026 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]